Across TCGA pan-cancer cohorts, OR6K2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OR6K2 data layer compared with 8 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OR6K2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR6K2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

UCEC, SCLC, and STAD are the cancer types where OR6K2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	II,III,IV	0.219	0.570	.033	3	view →
STAD	OS	Median	III,IV	0.149	0.502	.040	3	view →
SKCM	OS	Median	All	0.910	0.774	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: OR6K2 tumor-vs-normal RNA expression · all OR6K2 data types